Coherus Picks One Cancer and a Going-Concern Clock
A 30% headcount cut, an esophageal-only pipeline, and 12 months of cash — the stock is down 62% in 90 days and the science is no longer the question
CHRS · Earnings Call · 2026-11-09
Coherus spent years telling investors it could be an innovative oncology company with a broad Treg-depleting pipeline. On the Q3 2026 call, that story narrowed to a single disease. The company announced a 30% headcount reduction, a going-concern disclosure, and a strategic reset around tagmokitug in esophageal cancer. The tape is already voting: CHRS is down 61.6% over the last 90 trading days, including a 45% slide in the final nine sessions, leaving a $99M market cap and a drawdown of 98.3% from its 2015 peak. This is not a sector wave. It is a single-name liquidity event.
A Pivot That Reads as a Choice, Sounds Like a Constraint
The fresh keyword set is led by esophageal cancer, trailed by strategic prioritization and ex U.S. partnering. Esophageal was already in the keyword trail a year ago, but it has migrated from a secondary mention to the organizing principle of the company. That is a real change. Prior quarters were crowded with head and neck, colorectal, gastric, prostate, CCR8, Treg depletion and generic "tagmo in combination" language. Denny framed the narrowing as the end of a deliberate search: “we have spent the last few years transforming Coherus from a biosimilars company into an innovative oncology company focused on overcoming immune resistance in cancer.” — Dennis Lanfear, Chief Executive Officer · 2026-11-09 He described exploring "head and neck, esophageal, gastric, colorectal across various lines of therapy" before concluding esophageal is a best-in-disease opportunity across first and second line. The clinical case is not empty. In nine evaluable second-line patients at the 700 mg go-forward dose with toripalimab, the company reported a 33.3% confirmed ORR and 44.4% confirmed-plus-unconfirmed, against a chemo-only benchmark near 10%. Activity showed up in both histologies and in PD 1 refractory and PD-L1-low tumors, which is the entire point of the mechanism — Rosh Dias leaned hard on contribution of effect, noting the 300 mg arm produced no responses and all patients progressed by four months. That dose-response is the strongest single piece of evidence on the call. But the pivot answers a question analysts had been asking for months. In May, Douglas Tsao asked directly: “Do you think that you're in a position to continue to sort of prosecute all these opportunities? Or is there some prioritization that might need to happen?” — Douglas Tsao, Analyst · 2026-05-11 Denny's answer then was: “we are certainly funded through the '26 and all the '27 turning over of all the data cards.” — Dennis Lanfear, Chief Executive Officer · 2026-05-11 Seven months later the 10-Q carries going-concern language. The prioritization was not selected from strength; it was forced by the cash balance.The Arithmetic: $6M–$7M a Quarter Versus a $14M Product
Bryan McMichael laid out the liquidity plainly: “At the end of Q3 2026, we had $83.6 million in cash, cash equivalents and investments, which is down $21.7 million from $105.3 million at the end of Q2.” — Bryan McMichael, Chief Financial Officer · 2026-11-09 Then the sentence that matters more than any ORR:The 30% cut, roughly 140 to 100 FTEs, is meant to save $6M–$7M a quarter. It lowers the quarterly LOQTORZI revenue required to cover core costs from $30M–$35M to $25M–$30M. That single number is the whole bull case. Commercial is not broken, but it is slower and lumpier than the old cadence. Sameer reported “Third quarter net sales were $14 million, representing 3% quarter-over-quarter growth and 25% year-over-year growth.” — Sameer Goregaoker, Chief Commercial Officer · 2026-11-09 That missed the 10%–15% sequential target, and management trimmed the full-year outlook to $54M–$57M while still promising a $15M quarter in Q4. The distance from $14M to $25M is roughly 80% growth, and it has to happen while the company keeps paying to defend the franchise. The survey work is genuinely encouraging — 75% of surveyed oncologists now call LOQTORZI standard of care in NPC, and 57% know the six-year survival data. But awareness is not revenue, and the prior call's admission that more than half of addressable physicians had never prescribed it describes an education problem measured in quarters, not weeks. The structural backdrop is unforgiving. With total revenue of $14M in the July quarter, the company has already cut research spending to $21M, down 18% year over year and 72% from the 2021 peak. Free cash flow remained deeply negative at -$65M on a trailing basis. Cost discipline is real. It cannot finish the job alone.Without considering the potential benefit of the cost reductions, the payment of the milestone or proceeds from ex-U.S. deals, our cash runway is less than 12 months from the date of the 10-Q we filed today. As such, that quarterly report included going concern disclosures to reflect this.